Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil
Summary
SAN FRANCISCO--(BUSINESS WIRE)--Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 million in an oversubscribed Series B financing led by B Capital Group and Sanabil Investments. From the continued use of AtomNet® among research teams, Atomwise has gained a valuable breadth of experimental data, including the largest diversity of drug target sites, homology models, protein classes, and disease areas of any AI platform. We’re excited to continue to partner with the Atomwise team on its mission to develop new, more effective therapies.” A spokesperson for Sanabil Investments added, “We chose to lead this B round as Atomwise has shown clear leadership in developing better medicines for the world, and has become the number one global leader in applying and scaling its AI platform for drug discovery programs. Created in 2012, today, Atomwise performs hundreds of projects per year in partnership with some of the world’s largest pharmaceutical and agrochemical companies, as well as more than 200 universities and hospitals in 40 countries. It provides partners with patient and resilient capital, the ability to invest across multiple stages and funding rounds, and access to the GCC market.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
